ARTICLE | Clinical News
MacroGenics' margetuximab shows survival benefit in Phase III readout
February 8, 2019 8:43 PM UTC
MacroGenics Inc. (NASDAQ:MGNX) said Feb. 6 that margetuximab led to a survival benefit vs. Herceptin trastuzumab in the Phase III SOPHIA trial to treat HER2-positive metastatic breast cancer. MacroGenics is planning a BLA submission next half.
Founded in 2000, MacroGenics has no marketed products; margetuximab is its most advanced clinical candidate...
BCIQ Company Profiles
BCIQ Target Profiles
Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)